CBS 2019
CBSMD教育中心
中 文

科学研究

Abstract

Recommended Article

Prognostic value of fibrinogen in patients with coronary artery disease and prediabetes or diabetes following percutaneous coronary intervention: 5-year findings from a large cohort study Recommendations for Institutions Transitioning to High-Sensitivity Troponin Testing JACC Scientific Expert Panel A Novel Algorithm for Treating Chronic Total Coronary Artery Occlusion Optimal Timing of Intervention in NSTE-ACS Without Pre-Treatment The EARLY Randomized Trial Characterization of lesions undergoing ischemia-driven revascularization after complete revascularization versus culprit lesion only in patients with STEMI and multivessel disease - A DANAMI-3-PRIMULTI substudy Association of Silent Myocardial Infarction and Sudden Cardiac Death Major trials in coronary intervention from 2018 Interleukin-1 Beta as a Target for Atherosclerosis Therapy: Biological Basis of CANTOS and Beyond

Review Article2017 Jul 18;70(3):389-398.

JOURNAL:J Am Coll Cardiol. Article Link

Implantable Hemodynamic Monitoring for Heart Failure Patients

Abraham WT, Perl L. Keywords: disease management; hospitalization; patient readmission; pulmonary artery pressure; telemedicine

ABSTRACT


Rates of heart failure hospitalization remain unacceptably high. Such hospitalizations are associated with substantial patient, caregiver, and economic costs. Randomized controlled trials of noninvasive telemedical systems have failed to demonstrate reduced rates of hospitalization. The failure of these technologies may be due to the limitations of the signals measured. Intracardiac and pulmonary artery pressure-guided management has become a focus of hospitalization reduction in heart failure. Early studies using implantable hemodynamic monitors demonstrated the potential of pressure-based heart failure management, whereas subsequent studies confirmed the clinical utility of this approach. One large pivotal trial proved the safety and efficacy of pulmonary artery pressure-guided heart failure management, showing a marked reduction in heart failure hospitalizations in patients randomized to active pressure-guided management. "Next-generation" implantable hemodynamic monitors are in development, and novel approaches for the use of this data promise to expand the use of pressure-guided heart failure management.